RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
An unmet medical need exists for therapeutic regimens in transplantation that allow immediate
postoperative graft function, thereby improving graft survival. Delayed graft function (DGF)
after transplantation is the most common complication affecting kidney allographs in the
immediate transplant period. The specific aim of this study is to evaluate the effect of
recombinant human C1-inhibitor (rhC1INH), as a kidney recipient intra- and post operative
treatment strategy to decrease systemic inflammation and decrease the incidence of DGF from
donation after cardiac death donors (DCD).
Phase:
Phase 1
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
Pharming Technologies B.V.
Treatments:
Complement C1 Inhibitor Protein Pharmaceutical Solutions